Ipsen S.A. (IPN)
Market Closed
12 Jun, 15:30
€
157. 80
+0.7
+0.4456%
€
9.29B Market Cap
14.92 P/E Ratio
1.28% Div Yield
68,924 Volume
0 Eps
€ 157.1
Previous Close Want to track IPN and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
IPN closed today higher at €157.8, an increase of 0.4456% from yesterday's close, completing a monthly decrease of -5.3389% or -€8.9. Over the past 12 months, IPN stock gained 32.9402%.
IPN pays dividends to its shareholders, with the most recent payment made on Jun 05, 2026. The next estimated payment will be in 1 weeks ago on Jun 05, 2026 for a total of €1.6.
The last earnings report, released on Apr 23, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0.44%, based on the last three reports.
Ipsen S.A. has completed 1 stock splits, with the recent split occurring on Jun 01, 2010.
The company's stock is traded on 9 different exchanges and in various currencies, with the primary listing on LSE (EUR).
Ipsen S.A. (IPN) FAQ
What is the stock price today?
The current price is €157.80.
On which exchange is it traded?
Ipsen S.A. is listed on XPAR.
What is its stock symbol?
The ticker symbol is IPN.
Does it pay dividends? What is the current yield?
Yes, It pays dividends and the current yield is 1.28%.
What is its market cap?
As of today, the market cap is 9.29B.
Has Ipsen S.A. ever had a stock split?
Ipsen S.A. had 1 splits and the recent split was on Jun 01, 2010.
Ipsen S.A. Profile
| Specialty Retail Industry | Consumer Discretionary Sector | David Loew CEO | XPAR Exchange | FR0010259150 ISIN |
| FR Country | 5,358 Employees | 3 Jun 2026 Last Dividend | 1 Jun 2010 Last Split | - IPO Date |
Overview
Ipsen S.A. is a globally recognized biopharmaceutical company, with operations spanning worldwide. Established in 1929 and headquartered in Boulogne-Billancourt, France, the company has cemented its reputation as a leader in the development and commercialization of innovative drugs. Ipsen's key therapeutic focus areas include oncology, neuroscience, and rare diseases, addressing some of the most challenging medical conditions with cutting-edge research and developmental breakthroughs. Through a robust product pipeline and a dedication to improving patient outcomes, Ipsen S.A. demonstrates a relentless pursuit of therapeutic advancements to meet unmet medical needs.
Products and Services
- Cabometyx + Atezolizumab: Currently in phase III clinical trial targeting second line metastatic castration-resistant prostate cancer. This combination therapy showcases Ipsen's dedication to advancing oncology treatment options.
- Lenalidomide and Rituximab and Taverik: Engaged in phase III trials focusing on second line follicular lymphoma, highlighting the company’s efforts in combating haematological malignancies.
- Bylvay: In phase III for treating biliary atresia, Bylvay represents Ipsen’s commitment to addressing rare and serious liver conditions in pediatric populations.
- Dysport: Undergoing phase III clinical trials for chronic and episodic migraine, Dysport illustrates Ipsen’s innovations in the neurosciences realm, offering potential relief to millions suffering from debilitating migraine conditions.
- Fidrisertib: Targeting fibrodysplasia ossificans progressiva in a phase II clinical trial, positioning Ipsen at the forefront of research in rare skeletal disorders.
- Elafibranor: This compound is in phase II for primary sclerosing cholangitis, further showcasing Ipsen's ongoing efforts to treat rare liver diseases.
- IPN60250, IPN10200, IPN60210, and IPN60260: Ranging from phase II to I trials, these products demonstrate Ipsen's enduring commitment to expanding its portfolio in aesthetics, therapeutics, multiple myeloma, and viral cholestatic diseases, respectively.
- Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik: These are among Ipsen's flagship oncology products, addressing a variety of cancers and showcasing the breadth of Ipsen’s impact in oncology.
- Dysport (Neurosciences): Apart from its application in migraine, Dysport serves a vital role in other neurological conditions, emphasizing Ipsen’s broader commitment to neuroscience.
- Bylvay, NutropinAq, Increlex, and Sohonos (Rare Diseases): Serving patients with rare diseases, these products highlight Ipsen’s dedication to providing solutions for some of the most complex and uncommon medical conditions.
Contact Information
Address: 65 Quai Georges Gorse
Phone: 33 1 58 33 50 00
Website: https://www.ipsen.com
